Palbociclib and Pembrolizumab In Central Nervous System Metastases
Palbociclib and Pembrolizumab In Central Nervous System Metastases
Recruiting · NCT02896335 · Registry updated 2026-07-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Palbociclib and Pembrolizumab In Central Nervous System Metastases | Neoplasms by Site, brain disorder, central nervous system cancer, central nervous system disorder, neoplasm, nervous system disorder | Recruiting | Phase 2 | 2026-07-21 | NCT02896335 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Massachusetts General Hospital | 758 |
| Merck Sharp & Dohme LLC | 650 |
| Pfizer | 431 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana Farber Cancer Institute | Boston | United States | 300 |
| Massachusetts General Hospital | Boston | United States | 39 |